Plexiform neurofibromas is an uncommon variant of neurofibromatosis type 1 that arises from multiple nerves as bulging and deforming masses involving also connective tissue and skin folds. Neurofibromatosis is a genetic neurological disorder which can affect the skin, nerves, brain, and spinal cord. Neurofibromas or tumors, grow along the body's nerves or on or underneath the skin. There are three types of neurofibromatosis that are associated with unique symptoms and signs, Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and Schwannomatosis. Plexiform neurofibromas are essentially pathognomonic of neurofibromatosis type 1 (NF1) which is a common complication of neurofibromatosis. Plexiform neurofibromas are predominantly inherited tumors that can occur anywhere in the body. This includes the head and neck, extremities, areas around the spine and deep in the body where they may affect organs. Plexiform neurofibromas are usually diagnosed in early childhood. They are found in approximately 30% of patients with NF1. Plexiform neurofibromas diffusely involve long nerve segments and its branches, often extending beyond the epineurium into the surrounding tissue.

Market Dynamics

Adoption of inorganic strategies, such as product approval, by regulatory authority such as the U.S. Food and Drug Administration is expected to drive the global plexiform neurofibromas treatment market growth over the forecast period. For instance, in April 2020, AstraZeneca, a biopharmaceutical company, announced that they had received an approval from the U.S. Food and Drug Administration for Selumetinib under the brand name Koselugo, for pediatric patients, 2 years of age and older, with neurofibromatosis type 1. Selumetinib is a kinase inhibitor and the first therapy approved for pediatric patients with neurofibromatosis.

Key features of the study:

• This report provides an in-depth analysis of the global plexiform neurofibromas treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global plexiform neurofibromas treatment market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, SpringWorks Therapeutics, Alcaliber S.A, Teva Pharmaceutical Industries Ltd., Glenmark, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Apotex Inc., Mylan N.V., GSK plc., Solara Active Pharma Sciences Ltd., Abbott, Shanghai Kechow Pharma, Inc., Endo Pharmaceuticals Inc., Purdue Pharma L.P, Merck & Co., Inc., NFlection Therapeutics, Healx, and Array Biopharma
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global plexiform neurofibromas treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plexiform neurofibromas treatment market

Detailed Segmentation:

• Global Plexiform Neurofibromas Treatment Market, By Drug Class:
  • Selumetinib
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Anticonvulsants
  • Others (Tricyclic Antidepressants, etc.)
• Global Plexiform Neurofibromas Treatment Market, By Patient Population:
  • Pediatric
  • Adult
• Global Plexiform Neurofibromas Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Plexiform Neurofibromas Treatment Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Region/Country
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • AstraZeneca*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Pfizer Inc.
  • Sun Pharmaceuticals Industries Limited
  • Mallinckrodt Pharmaceuticals
  • SpringWorks Therapeutics
  • Alcaliber S.A
  • Teva Pharmaceutical Industries Ltd.
  • Glenmark
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma
  • Apotex Inc.
  • Mylan N.V.
  • GSK plc.
  • Solara Active Pharma Sciences Ltd.
  • Abbott
  • Shanghai Kechow Pharma, Inc.
  • Endo Pharmaceuticals Inc.
  • Purdue Pharma L.P
  • Merck & Co., Inc.
  • NFlection Therapeutics
  • Healx
  • Array Biopharma

“*” marked represents similar segmentation in other categories in the respective section.